The United Kingdom and the United States have established a major bilateral deal that will guarantee zero levies on British medicine exports going into the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to boost spending on medicines through the NHS. This pledge ensures that duties on these key goods will be held at zero for a duration of 36 months.
This agreement comes after previous threats to dramatically increase tariffs on patented pharmaceutical products, with increases floated as high as 100%.
"This deal with the Britain strengthens the worldwide climate for new treatments and brings long-overdue balance to U.S.–U.K. drug exports," an announcement declared.
Trade Significance
Medicines constitute one of the the United Kingdom's biggest export categories to the United States, which is by far the largest market for major companies like GSK and AstraZeneca.
Export figures show that in the year leading up to the third quarter, the UK sold medicines worth billions to the US. This figure accounted for a significant portion of British export trade in that period.
"This guarantee secures work, increases funding and facilitates the UK to emerge as a international leader for medical research," a government official remarked.
Detailed UK Commitments
The pact includes several notable commitments from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a target to double total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The sum manufacturers must return to the NHS to stay within budget will be restricted at 15%. Last year, repayments were more than 20%.
Broader Context
This agreement takes place against a long-running row between the drug companies and the UK government over drug pricing and NHS adoption.
The disagreement were heightened by arguments that American consumers were charged several times more for the equivalent treatments than patients in the UK and Europe.
Recently, several major drug company projects in the UK have been paused or cancelled, while major funding commitments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had decreased as a share of its resources over the previous ten-year period.
